Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05827926 · ClinicalTrials.gov registry record · Phase 1
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
A Phase 1 study of Influenza and SARS-CoV-2, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,758
- Enrollment target
- 20
- Study locations
NCT05827926 is a Phase 1 study of Influenza and SARS-CoV-2 that has completed, run by ModernaTX. The registered enrollment target is 1,758 participants, below the 36,793-participant average among 156 other Influenza trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05827926, a Phase 1 study of Influenza and SARS-CoV-2, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,758 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults. The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and \<50 years of age.
Conditions Studied
Interventions
- BIOLOGICAL Influenza Vaccine 1
- BIOLOGICAL mRNA-1083.1
- BIOLOGICAL mRNA-1083.2
- BIOLOGICAL mRNA-1083.3
- BIOLOGICAL Investigational Influenza Vaccine 1
Study Locations (20)
Florida
- Accel Research Sites - DeLand
- CenExel - Hollywood
- Nature Coast Clinical Research - Inverness
- Jacksonville Center For Clinical Research - Jacksonville
- Accel Research Sites - Maitland
- Suncoast Research Group - Miami
California
- Benchmark Research - Colton
- Marvel Clinical Research - Huntington Beach
- Central Valley Research - Modesto
- Benchmark Research - Sacramento
Georgia
- Centricity Research - Columbus
- Accel Research Site - Decatur
- CenExel iResearch - Decatur
- Lifeline Primary Care - Lilburn
Illinois
- Koch Family Medicine - Morton
- Optimal Research - Peoria
- DM Clinical Research - River Forest
Arizona
- Chandler Clinical Trials - Chandler
Colorado
- Tekton Research - Longmont
Kansas
- Johnson County Clin-Trials - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,758 participants |
| Start Date | 2023-04-14 |
| Est. Completion | 2024-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05827926
The ClinicalTrials.gov registry entry for NCT05827926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,758 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,793-participant average among 156 other Influenza trials with a reported enrollment target (95% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Influenza appearing as the primary indexed condition, and to 5 interventions - of which Influenza Vaccine 1 is the first listed.
NCT05827926 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05827926 about?
NCT05827926 is a clinical study titled "A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults". The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults. Th...
What is the current status of trial NCT05827926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,758 participants. The study started on 2023-04-14. Estimated completion is 2024-12-03.
What conditions does trial NCT05827926 study?
This clinical trial studies the following conditions: Influenza, SARS-CoV-2.
What interventions are being tested in trial NCT05827926?
The interventions under investigation include: Influenza Vaccine 1 (BIOLOGICAL), mRNA-1083.1 (BIOLOGICAL), mRNA-1083.2 (BIOLOGICAL), mRNA-1083.3 (BIOLOGICAL), Investigational Influenza Vaccine 1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05827926?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05827926 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
pH1N1 Blinded Challenge Study
RECRUITING · Phase 1
-
A/Texas Flu Challenge
RECRUITING · Phase 1
-
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
RECRUITING · Phase 1
-
Influenza Human Challenge Model
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
ACTIVE NOT RECRUITING · Phase 1
-
Pilot Influenza Challenge Study
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.